Treatment extends life for men with prostate cancer

June 1, 2014
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

A new treatment has been shown to extend the lifespans of men with advanced prostate cancer by as much as one year, researchers said Sunday.

The study involved 790 men who were diagnosed with , meaning the disease had spread beyond the prostate.

By adding the chemotherapy drug docetaxel to standard , known as (ADT), fewer patients died and many lived longer.

After 29 months, 136 men had died in the ADT alone group and 101 in the combination group.

The median, or midpoint, overall survival for the ADT group was 44 months, while those who also received docetaxel lived 57.6 months.

ADT is an effective therapy but eventually most patients become resistant to it, allowing the cancer to spread.

Some 30,000 men die of hormone-resistant prostate cancer each year in the United States.

"Hormone has been a standard treatment for prostate cancer since the 1950s," said lead study author Christopher Sweeney of the Dana Farber Cancer Institute in Boston, Massachusetts.

"This is the first study to identify a strategy that prolongs survival in newly diagnosed metastatic ," he added, describing the benefit as "substantial."

The research was presented at the American Society of Clinical Oncology annual conference.

"These results demonstrate how we can use 'old tools' in new, more powerful ways to improve and extend patients' lives," said ASCO president Clifford Hudis.

Explore further: Study shows benefits for men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy

Related Stories

Study shows benefits for men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy

December 6, 2013
Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to ...

ASCO: No benefit for immediate ADT after PSA-only relapse

May 22, 2014
(HealthDay)—For men with a prostate-specific antigen (PSA)-only-based relapse after prostate surgery or radiation therapy, there seems to be little or no survival benefit for immediate initiation of androgen deprivation ...

Radiation for prostate cancer linked to secondary cancers, study finds

May 30, 2014
Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center.

Radiotherapy plus hormone therapy cuts prostate cancer death in half, shows long-term study

January 30, 2014
Combination treatment more than halves mortality rates for prostate cancer, reports Norwegian health journal Dagens Medisin.

Primary androgen deprivation therapy ineffective for most men with early prostate cancer

March 17, 2014
A study of more than 15,000 men with early stage prostate cancer finds that those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received ...

Patients receiving ADT should be counseled to improve mental and emotional well-being

January 23, 2014
A new study published in the Journal of Urology reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, although there ...

Recommended for you

Researchers find adult stem cell characteristics in aggressive cancers from different tissues

September 19, 2018
UCLA researchers have discovered genetic similarities between the adult stem cells responsible for maintaining and repairing epithelial tissues—which line all of the organs and cavities inside the body—and the cells that ...

Ketogenic diet reduces body fat in women with ovarian or endometrial cancer

September 19, 2018
Women with ovarian or endometrial cancer who followed the ketogenic diet for 12 weeks lost more body fat and had lower insulin levels compared to those who followed the low-fat diet recommended by the American Cancer Society, ...

Eating foods with low nutritional quality ratings linked to cancer risk in large European cohort

September 18, 2018
The consumption of foods with higher scores on the British Food Standards Agency nutrient profiling system (FSAm-NPS), reflecting a lower nutritional quality, is associated with an increased risk of developing cancer, according ...

Could the zika virus fight the brain cancer that killed john McCain?

September 18, 2018
(HealthDay)—Preliminary research in mice suggests that the Zika virus might be turned from foe into friend—enlisted to curb deadly glioblastoma brain tumors.

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

September 18, 2018
A little p63 goes a long way in embryonic development—and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs. But once this early work is done, p63 goes silent, sitting quietly ...

Enlarged genotype-phenotype correlation for a three-base pair deletion in neurofibromatosis type 1

September 18, 2018
International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.